BHC · Bausch Health Companies Inc.
$6.44
-0.37 (-5.43%)
At close · Aug 21
Market Cap
$2.41B
Shares
373.99M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$10.27B
+6.7%
FY2025
Net Income
$157M
+441.3%
FY2025
Gross Margin
71.27%
-2.1pp
FY2017
Operating Margin
17.66%
+1.6pp
FY2025
Diluted EPS
$0.42
+423.1%
FY2025
Operating Cash Flow
$1.4B
-12.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.85B | $10.27B | $9.63BG | $8.76BG | $8.12B | $8.43B | $8.03B | $8.6B | $8.38B | $8.72B | $9.67B | $10.45B | $8.21B | $5.77B | $3.48B | $2.43B | $1.18B | $820.43M | $757.18M | |
| $2.43B | — | — | — | — | — | — | — | — | $2.51B | $2.57B | $2.53B | $2.18B | $1.85B | $905.1M | $683.75M | $395.6M | $204.31M | $197.17M | |
| $6.07B | — | — | — | — | — | — | — | — | $6.22B | $7.1B | $7.92B | $6.03B | $3.92B | $2.58B | $1.74B | $785.64M | $616.12M | $560.01M | |
| — | — | — | — | — | — | — | — | — | 71.27% | 73.41% | 75.76% | 73.46% | 68% | 73.99% | 71.83% | 66.51% | 75.1% | 73.96% | |
| $663M | $629M | $616M | $604M | $529M | $465M | $452M | $471M | $413M | $361M | $421M | $334M | $246M | $156.8M | $79.1M | $65.69M | $68.31M | $47.58M | $69.81M | |
| $3.45B | $3.44B | $3.3B | $2.92B | $2.63B | $2.62B | $2.37B | $2.55B | $2.47B | $2.58B | $2.81B | $2.7B | $2.03B | $1.31B | $756.1M | $572.47M | $276.55M | $167.63M | $188.92M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $1.9B | $931.44M | $566.99M | $228.93M | $113.91M | — | |
| — | $1.21B | $1.27B | $1.26B | $1.39B | $1.55B | $1.83B | $2.08B | $2.82B | $2.86B | $2.87B | $2.47B | $1.61B | $2.02B | $986.2M | $612.6M | $254.5M | $149.26M | — | |
| $32M | — | — | — | — | — | $22M | $31M | $22M | $52M | $132M | $362M | $382M | $462M | $267.1M | $97.67M | $140.84M | $30.03M | $70.2M | |
| $9.97B | $8.45B | $8.08B | $7.79B | $7.67B | $7.98B | $7.35B | $8.8B | $10.76B | $8.62B | $10.24B | $8.92B | $6.21B | $6.18B | $3.4B | $2.13B | $1.29B | $639.28M | $633.07M | |
| $883M | $1.81B | $1.55B | $963M | $454M | $450M | $676M | -$203M | -$2.38B | $102M | -$566M | $1.53B | $2B | -$409.5M | $79.7M | $299.96M | -$110.09M | $181.15M | $124.11M | |
| — | 17.66% | 16.06% | 11% | 5.59% | 5.34% | 8.42% | -2.36% | -28.45% | 1.17% | -5.85% | 14.62% | 24.38% | -7.1% | 2.29% | 12.36% | -9.32% | 22.08% | 16.39% | |
| — | $3.02B | $2.81B | $2.23B | $1.85B | $2B | $2.5B | $1.87B | $435M | $2.96B | $2.3B | $3.99B | $3.62B | $1.61B | $1.07B | $912.56M | $144.42M | $330.41M | — | |
| $45M | $48M | $33M | $26M | $14M | $7M | $13M | $12M | $11M | $12M | $8M | $4M | $5M | $8M | $6M | $4.08M | $1.29M | $1.12M | $9.4M | |
| — | -$142M | -$247M | -$28M | -$35M | -$373M | -$502M | -$1.43B | $20M | $348M | -$73M | -$295M | $263M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | $293M | $5.8M | $2.1M | $22.78M | -$5.55M | $17.59M | -$4.53M | |
| -$732M | $367M | $167M | -$390M | -$129M | -$1.02B | -$934M | -$1.84B | -$4.15B | -$1.74B | -$2.44B | -$155M | $1.05B | -$1.31B | -$394.2M | -$18M | -$236.26M | $174.96M | — | |
| $361M | $247M | $239M | $221M | $83M | -$87M | -$375M | -$54M | -$10M | -$4.15B | -$27M | $133M | $174M | -$450.8M | -$278.2M | -$177.56M | -$28.07M | -$1.5M | -$73M | |
| -$1.1B | $157M | -$46M | -$592M | -$225M | -$948M | -$560M | -$1.79B | -$4.14B | $2.4B | -$2.41B | -$288M | $880M | -$863.6M | -$116M | $159.56M | $366.67M | $406.6M | $199.9M | |
| — | 1.53% | -0.48% | -6.76% | -2.77% | -11.24% | -6.98% | -20.79% | -49.45% | 27.56% | -24.89% | -2.76% | 10.72% | -14.97% | -3.33% | 6.57% | 31.04% | 49.56% | 26.4% | |
| $5M | -$37M | -$26M | -$19M | $13M | $11M | $1M | $5M | $4M | $0 | $1M | $4M | -$1M | $2.5M | $0 | $0 | — | — | — | |
| — | — | — | — | — | — | -$560M | -$1.79B | -$4.15B | $2.4B | -$2.41B | -$292M | $881M | -$866.1M | -$116M | $159.56M | -$208.19M | $176.46M | — | |
| -$1.13B | $576M | -$344M | -$417M | -$494M | -$1.08B | -$607M | -$1.74B | -$4.39B | $2.62B | -$2.98B | -$918M | $98M | -$879.5M | $44.2M | -$218.89M | -$152.93M | — | — | |
| USD/shares | — | $0.42 | -$0.13 | -$1.62 | -$0.62 | -$2.64 | -$1.58 | -$5.08 | -$11.81 | $6.86 | -$6.94 | -$0.85 | $2.63 | -$2.70 | -$0.38 | $0.52 | -$1.06 | $1.11 | $1.25 |
| USD/shares | — | $0.42 | -$0.13 | -$1.62 | -$0.62 | -$2.64 | -$1.58 | -$5.08 | -$11.81 | $6.83 | -$6.94 | -$0.85 | $2.58 | -$2.70 | -$0.38 | $0.49 | -$1.06 | $1.11 | $1.25 |
| shares | — | 370.9M | 368M | 364.9M | 362M | 358.9M | 355M | 352.1M | 351.3M | 350.2M | 347.3M | 342.7M | 335.4M | 321M | 305.4M | 304.66M | 195.81M | 158.24M | 159.73M |
| shares | — | 375M | 368M | 364.9M | 362M | 358.9M | 355M | 352.1M | 351.3M | 351.8M | 347.3M | 342.7M | 341.5M | 321M | 305.4M | 326.12M | 195.81M | 158.51M | 159.73M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2017: $1.14B in buybacks, $683.72M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.96×
Peer median 2.12×
EV/EBIT
24.15×
Peer median 15.02×
P/E (TTM)
—
Peer median 17.42×
Peer medians compare against the 45 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Bausch Lomb | $5,101,000,000 | $4,791,000,000 | $4,146,000,000 | $3,768,000,000 | $3,765,000,000 | $3,415,000,000 | $3,778,000,000 | — |
| Salix Segment | $2,578,000,000 | $2,333,000,000 | $2,250,000,000 | $2,090,000,000 | $2,074,000,000 | $1,904,000,000 | $2,022,000,000 | $1,749,000,000 |
| International Rx | $1,132,000,000 | $1,111,000,000 | $1,071,000,000 | $988,000,000 | $1,166,000,000 | $1,181,000,000 | $1,154,000,000 | — |
| Diversified Segment | $937,000,000 | $950,000,000 | $943,000,000 | $978,000,000 | $1,121,000,000 | — | — | — |
| Solta Medical Segment | $518,000,000 | $440,000,000 | $347,000,000 | $300,000,000 | $308,000,000 | $253,000,000 | — | — |
| Baushand Lomb International Segment | — | — | — | — | — | $4,408,000,000 | $4,739,000,000 | $4,664,000,000 |
| Diversified Products Segment | — | — | — | — | $1,121,000,000 | $1,274,000,000 | $1,087,000,000 | $1,350,000,000 |
| Ortho Dermatologics Segment | — | — | — | — | $564,000,000 | $548,000,000 | $560,000,000 | $617,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States and Puerto Rico | $6,138,000,000 | $5,767,000,000 | $5,194,000,000 | $4,836,000,000 | $4,887,000,000 | $4,791,000,000 | $5,164,000,000 | $5,011,000,000 |
| Other Countries | $1,153,000,000 | $1,083,000,000 | $1,011,000,000 | $887,000,000 | $1,066,000,000 | $1,112,000,000 | $995,000,000 | $1,127,000,000 |
| China | $493,000,000 | $496,000,000 | $441,000,000 | $413,000,000 | $490,000,000 | $341,000,000 | $368,000,000 | $361,000,000 |
| Canada | $417,000,000 | $402,000,000 | $366,000,000 | $351,000,000 | $343,000,000 | $331,000,000 | $339,000,000 | $319,000,000 |
| Poland | $382,000,000 | $350,000,000 | $319,000,000 | $278,000,000 | $280,000,000 | $238,000,000 | $231,000,000 | $218,000,000 |
| Mexico | $278,000,000 | $315,000,000 | $322,000,000 | $276,000,000 | $256,000,000 | $225,000,000 | $228,000,000 | $211,000,000 |
| France | $249,000,000 | $230,000,000 | $214,000,000 | $203,000,000 | $208,000,000 | $179,000,000 | $201,000,000 | $205,000,000 |
| South Korea | $234,000,000 | $146,000,000 | $93,000,000 | $77,000,000 | $76,000,000 | $68,000,000 | — | — |
| Russia | $198,000,000 | $161,000,000 | $148,000,000 | $181,000,000 | $160,000,000 | $137,000,000 | $180,000,000 | $154,000,000 |
| Japan | $192,000,000 | $188,000,000 | $194,000,000 | $200,000,000 | $230,000,000 | $226,000,000 | $241,000,000 | $226,000,000 |
| Germany | $176,000,000 | $159,000,000 | $152,000,000 | $147,000,000 | $154,000,000 | $144,000,000 | $150,000,000 | $170,000,000 |
| United Kingdom | $141,000,000 | $135,000,000 | $125,000,000 | $115,000,000 | $116,000,000 | $86,000,000 | $115,000,000 | $117,000,000 |
| Spain | $109,000,000 | $99,000,000 | $92,000,000 | $84,000,000 | $88,000,000 | $78,000,000 | $86,000,000 | $83,000,000 |
| Italy | $106,000,000 | $94,000,000 | $86,000,000 | $76,000,000 | $80,000,000 | $71,000,000 | $85,000,000 | — |
| Egypt | — | — | — | — | — | — | $218,000,000 | $178,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical Products | $4,747,000,000 | $4,396,000,000 | $3,909,000,000 | $3,642,000,000 | $3,743,000,000 | $3,680,000,000 | $4,079,000,000 | $4,028,000,000 |
| Device Products | $2,439,000,000 | $2,240,000,000 | $1,997,000,000 | $1,872,000,000 | $1,903,000,000 | $1,566,000,000 | $1,717,000,000 | $1,640,000,000 |
| Over the Counter Products | $2,008,000,000 | $1,903,000,000 | $1,797,000,000 | $1,619,000,000 | $1,538,000,000 | $1,430,000,000 | $1,447,000,000 | $1,412,000,000 |
| Branded and Other Generic Products | $962,000,000 | $979,000,000 | $960,000,000 | $892,000,000 | $1,144,000,000 | $1,248,000,000 | $1,246,000,000 | $1,191,000,000 |
| Other Revenues | $110,000,000 | $107,000,000 | $94,000,000 | $99,000,000 | $106,000,000 | $103,000,000 | $112,000,000 | $109,000,000 |
| Product And Service Other | $110,000,000 | $107,000,000 | $94,000,000 | $99,000,000 | $106,000,000 | $103,000,000 | $112,000,000 | $109,000,000 |
| Price Appreciation Credit | $18,000,000 | $18,000,000 | $11,000,000 | $10,000,000 | $17,000,000 | $15,000,000 | $11,000,000 | $31,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Salix Segment | $1,925,000,000 | $1,602,000,000 | $1,548,000,000 | $1,489,000,000 | $1,493,000,000 | $1,338,000,000 | $1,349,000,000 | $1,149,000,000 |
| Bausch Lomb | $1,125,000,000 | $1,108,000,000 | $980,000,000 | $874,000,000 | $958,000,000 | $909,000,000 | $1,117,000,000 | — |
| Diversified Segment | $627,000,000 | $626,000,000 | $586,000,000 | $612,000,000 | $722,000,000 | — | — | — |
| International Rx | $334,000,000 | $376,000,000 | $335,000,000 | $324,000,000 | $403,000,000 | $386,000,000 | $352,000,000 | — |
| Solta Medical Segment | $232,000,000 | $213,000,000 | $161,000,000 | $135,000,000 | $167,000,000 | $131,000,000 | — | — |
| Baushand Lomb International Segment | — | — | — | — | — | $1,159,000,000 | $1,332,000,000 | $1,330,000,000 |
| Diversified Products Segment | — | — | — | $612,000,000 | $722,000,000 | $814,000,000 | $801,000,000 | $1,012,000,000 |
| Ortho Dermatologics Segment | — | — | — | — | $265,000,000 | $228,000,000 | $216,000,000 | $257,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Bausch Lomb | 22.1% | 23.1% | 23.6% | 23.2% | 25.4% | 26.6% | 29.6% | — |
| Salix Segment | 74.7% | 68.7% | 68.8% | 71.2% | 72% | 70.3% | 66.7% | 65.7% |
| International Rx | 29.5% | 33.8% | 31.3% | 32.8% | 34.6% | 32.7% | 30.5% | — |
| Diversified Segment | 66.9% | 65.9% | 62.1% | 62.6% | 64.4% | — | — | — |
| Solta Medical Segment | 44.8% | 48.4% | 46.4% | 45% | 54.2% | 51.8% | — | — |
| Baushand Lomb International Segment | — | — | — | — | — | 26.3% | 28.1% | 28.5% |
| Diversified Products Segment | — | — | — | — | 64.4% | 63.9% | 73.7% | 75% |
| Ortho Dermatologics Segment | — | — | — | — | 47% | 41.6% | 38.6% | 41.7% |
Key facts
CIK
885590
CUSIP
071734107
13F (30d)
204 filings
203 filers
Visit website
Investor relations